100+ peptides — vial sizes, ratios, and doses. Click Calc → on any row to open the calculator pre-loaded. (Multi-peptide blends with batch-specific ratios are marked N/A.)
| Peptide | Category | Common vial | BAC water | Concentration | Research dose | → Units (U-100) | Protocol window | Cites | |
|---|---|---|---|---|---|---|---|---|---|
BPC-157 Pentadecapeptide |
Recovery | 5 mg | 2 mL | 2.5 mg/mL | 200–500 mcg 1–2× daily | 10 units (250 mcg) | 4–6 wks on / 2–4 off | 42 | |
TB-500 Thymosin β4 fragment |
Recovery | 10 mg | 3 mL | 3.3 mg/mL | 2–2.5 mg 1–2× weekly | 60 units (2 mg) | 4–6 wks loading, then maint. | 28 | |
BPC-157 + TB-500 Blend 5 mg BPC + 5 mg TB (10 mg total) |
Recovery | 10 mg | 2 mL | 5 mg/mL (2.5 each) | 250–500 mcg of each, EOD to daily | 10 units (500 mcg blend) | 4–8 wks on / 2–4 off | 12 | |
KPV Lys-Pro-Val tripeptide |
Recovery | 10 mg | 2 mL | 5 mg/mL | 200–500 mcg daily | 4 units (200 mcg) | Continuous, monitor | 14 | |
LL-37 Cathelicidin antimicrobial |
Recovery | 5 mg | 2 mL | 2.5 mg/mL | 100–500 mcg daily | 4 units (100 mcg) | 2 wks on / 2 off | 19 | |
Thymosin Alpha-1 28-aa immune peptide |
Immune | 5 mg | 2 mL | 2.5 mg/mL | 1.6 mg 2× weekly | 64 units (1.6 mg) | Continuous, physician-guided | 23 | |
Semaglutide GLP-1 receptor agonist |
Metabolic | 5 mg | 2 mL | 2.5 mg/mL | 0.25 mg → 2.4 mg weekly (titrate) | 10 units (0.25 mg start) | 4-wk titration then maint. | 45 | |
Tirzepatide GLP-1 / GIP dual |
Metabolic | 30 mg | 3 mL | 10 mg/mL | 2.5 mg → 15 mg weekly (titrate) | 25 units (2.5 mg start) | 4-wk titration steps | 31 | |
Retatrutide GLP-1 / GIP / glucagon |
Metabolic | 10 mg | 3 mL | 3.3 mg/mL | 2 mg → 12 mg weekly (titrate) | 60 units (2 mg start) | Phase 3 trial protocol | 18 | |
AOD-9604 HGH fragment 176-191 |
Metabolic | 10 mg | 2 mL | 5 mg/mL | 250–500 mcg daily | 5 units (250 mcg) | 4–8 wks | 11 | |
Cagrilintide Amylin analog |
Metabolic | 10 mg | 2 mL | 5 mg/mL | 0.3 mg → 2.4 mg weekly | 6 units (0.3 mg start) | 16-wk titration | 9 | |
CJC-1295 (no DAC) GHRH analog · short-acting |
GH sec. | 10 mg | 2 mL | 5 mg/mL | 100 mcg 1–3× daily | 2 units (100 mcg) | 5 days on / 2 off, 8-wk cycles | 16 | |
CJC-1295 No DAC + Ipamorelin 5 mg CJC + 5 mg Ipa (10 mg total) |
GH sec. | 10 mg | 2 mL | 5 mg/mL (2.5 each) | 100 mcg of each nightly, titrate slowly | 4 units (200 mcg blend) | 8–12 wks, then 4+ wks off | 2 | |
Ipamorelin Selective ghrelin agonist |
GH sec. | 10 mg | 2 mL | 5 mg/mL | 100–300 mcg 1–3× daily | 4 units (200 mcg) | 5 days on / 2 off | 21 | |
Sermorelin GHRH 1-29 bioidentical |
GH sec. | 10 mg | 2 mL | 5 mg/mL | 200–300 mcg before sleep | 4 units (200 mcg) | Continuous, monitor IGF-1 | 27 | |
Tesamorelin GHRH analog · long-acting |
GH sec. | 10 mg | 2 mL | 5 mg/mL | 1–2 mg daily | 20 units (1 mg) | 12–26 wks | 14 | |
GHRP-6 Ghrelin agonist |
GH sec. | 5 mg | 2 mL | 2.5 mg/mL | 100–150 mcg 1–3× daily | 4 units (100 mcg) | 5 days on / 2 off | 12 | |
Epitalon Ala-Glu-Asp-Gly |
Longevity | 10 mg | 2 mL | 5 mg/mL | 1–5 mg daily | 20 units (1 mg) | 10–20 day course, 2–3×/yr | 17 | |
NAD+ Coenzyme |
Longevity | 1000 mg | 10 mL | 100 mg/mL | 50–100 mg 3× weekly | 50 units (50 mg) | 4–8 wks loading | 22 | |
SS-31 (Elamipretide) Mito-targeted tetrapeptide |
Longevity | 10 mg | 2 mL | 5 mg/mL | 1–5 mg daily | 20 units (1 mg) | Continuous in trials | 15 | |
MOTS-C Mitochondrial-derived |
Longevity | 10 mg | 2 mL | 5 mg/mL | 1–5 mg 2–3× weekly | 20 units (1 mg) | 6–8 wks | 10 | |
Semax ACTH fragment analog |
Cognitive | 10 mg | 1 mL | 10 mg/mL | 200–600 mcg daily | 2–6 units (200–600 mcg) | 2–4 wks on / 2 off | 13 | |
Selank Tuftsin analog |
Cognitive | 10 mg | 1 mL | 10 mg/mL | 250–500 mcg daily | 2.5–5 units (250–500 mcg) | 2–3 wks on / 1 off | 11 | |
DSIP Delta sleep-inducing |
Cognitive | 10 mg | 2 mL | 5 mg/mL | 100–500 mcg before sleep | 2 units (100 mcg) | 2–4 wks | 8 | |
GHK-Cu Copper-binding tripeptide |
Skin | 10 mg | 2 mL | 5 mg/mL | 1–3 mg topical or subQ | 20 units (1 mg) | Ongoing / topical | 33 | |
AHK-Cu Copper-binding tripeptide (hair) |
Skin | 100 mg | 10 mL | 10 mg/mL | 1–2 mg topical or subQ | 10 units (1 mg) | Ongoing / topical | 8 | |
Melanotan II α-MSH analog |
Skin | 10 mg | 2 mL | 5 mg/mL | 250 mcg loading → 500 mcg maint. | 5 units (250 mcg) | 2-wk loading, then 2×/wk | 9 | |
PT-141 Bremelanotide · MC4 agonist |
Metabolic | 10 mg | 2 mL | 5 mg/mL | 1–1.75 mg as-needed | 20 units (1 mg) | PRN, ≤8×/month | 14 | |
Oxytocin Oxytocin acetate · 5 mg vial |
Cognitive | 5 mg | 2 mL | 2.5 mg/mL | 50–100 mcg | 2–4 units (50–100 mcg) | PRN | 36 | |
Vitamin B12 Methylcobalamin · pre-mixed liquid |
Longevity | 10 mL | Pre-mixed — none | 1 mg/mL (check label) | 0.5–1 mg 1–3× weekly | 50 units (0.5 mg) | Ongoing | 6 | |
Klow GHK-Cu + BPC-157 + TB-500 + KPV blend (10 mg) |
Skin | 10 mg | 2 mL | 5 mg/mL blend | ~0.5 mg blend daily | 10 units (0.5 mg) | 4–6 wks on / 2–4 off | 6 | |
Snap-8 Argireline extension · subcutaneous |
Skin | 10 mg | 2 mL | 5 mg/mL | 100–250 mcg | 2 units (100 mcg) | 2–4 wks | 5 | |
Kisspeptin-10 KISS1-derived decapeptide |
Skin | 10 mg | 2 mL | 5 mg/mL | 50–100 mcg | 1–2 units (50–100 mcg) | PRN / short course | 14 | |
Glutathione Tripeptide antioxidant |
Longevity | 600 mg | 2 mL | 300 mg/mL | 100–300 mg | 3–10 units (100–300 mg) | Ongoing, 2–3× weekly | 22 |